Showing results (1831-1840 of 1,915) with videos related to

Sort By:
Pageof 192
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Nature|November 23, 2018
TDP-43 and RNA form amyloid-like myo-granules in regenerating muscleThomas O Vogler, Joshua R Wheeler, Eric D Nguyen, et al.
Blood|September 2, 2025
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutationsNaranie Shanmuganathan, David T Yeung, Carol Wadham, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Leukemia|January 8, 2021
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
British Journal of Pharmacology|July 1, 1996
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4B Hughes, D Howat, H Lisle, et al.
Plos One|December 4, 2008
The evolution of invasiveness in garden antsSylvia Cremer, Line V Ugelvig, Falko P Drijfhout, et al.
Annals of Internal Medicine|February 21, 2018
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label StudyFrançois-Xavier Mahon, Carla Boquimpani, Dong-Wook Kim, et al.
Blood|December 15, 2025
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST TrialJorge E Cortes, Timothy P Hughes, Jianxiang Wang, et al.
Pain|May 27, 2008
The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic painPenny C Staton, Jon P Hatcher, Deborah J Walker, et al.
Pageof 192